# Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

> **NCT01179048** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 9341 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01179048
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-31
- **Primary completion:** 2015-12-17
- **Final completion:** 2015-12-17
- **Target enrollment:** 9341 (ACTUAL)
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01179048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01179048, "Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01179048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*